Floatz logo

Abm-168

NF1 Mutation

ABM Therapeutics CorporationPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

14 Active assets in the NF1 Mutation cohort.

Asset / SponsorPhaseRating
gsk1120212
Novartis Pharmaceuticals
Phase 4B
Dabrafenib
Novartis Pharmaceuticals
Phase 4B
Anti-Thymoglobulin, Rabbit
Masonic Cancer Center, University of Minnesota
Phase 2CCC
Alpha/Beta T Cell-Depleted Hematopoietic Stem Cells
Masonic Cancer Center, University of Minnesota
Phase 2CCC
Fludarabine
Masonic Cancer Center, University of Minnesota
Phase 2CCC

View all 14 →

Same molecule, other indications

Abm-168 is also rated in:

RAF MutationDormant
CC
Indicative ·
43 / 100
View asset →
RAS MutationDormant
CC
Indicative ·
41 / 100
View asset →
cancerDormant
C
Indicative ·
36 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →